Talquetamab in Relapsed/Refractory Multiple Myeloma: Extended Follow-Up From MonumenTAL-1 and Real-World Outpatient Step-Up Dosing

home / between-the-lines / talquetamab-in-relapsed-refractory-multiple-myeloma-extended-follow-up-from-monumental-1

Binod Dhakal, MD; and Leonid Shunyakov, MD, discuss how talquetamab (targeting GPRC5D) represents a breakthrough therapy for patients with relapsed/refractory multiple myeloma, demonstrating unprecedented 3-year overall survival rates of 45% to 61% with lower infection risks compared with BCMA-directed therapies, while addressing optimal sequencing strategies, outpatient management approaches, and the potential for earlier-line usage to maximize patient outcomes.

2 experts in this video

EP. 1: Later R/R MM Treatment Landscape and Unmet Needs

Binod Dhakal, MD, MS;Leonid Shunyakov, MD
June 13th 2025

Panelists discuss the unmet need for effective therapies in early-relapse multiple myeloma, where patients have exhausted standard treatments but do not yet qualify for bispecific therapies or CAR T cells.

2 experts in this video

EP. 2: ASCO 2025: MonumenTAL-1 Extended Follow-Up for Talquetamab in R/R MM

Binod Dhakal, MD, MS;Leonid Shunyakov, MD
June 13th 2025

Panelists discuss how talquetamab targets GPRC5D, which is heavily expressed on malignant plasma cells but not normal B cells, potentially explaining lower infection rates compared with B-cell maturation antigen (BCMA)–targeted therapies.